Piper Jaffray and Maxim have a target price of $1, Aegis Capital of $1.5.
In a report published March 11, 2013, Aegis Capital initiated coverage on Inovio Pharmaceuticals (NYSE: INO [FREE Stock Trend Analysis]) with a Buy rating and $1.50 price target.
Aegis Capital noted, “We are initiating coverage of Inovio Pharmaceuticals, Inc. with a Buy rating and a 12-month price target of $1.50 per share. In our view, Inovio is a highly diversified developer of differentiated DNA-based vaccines, which could represent novel and highly effective ways to treat various inflammatory, oncology-focused and infectious disorders. Our price target is derived from a comparable universe-based valuation methodology, which forecasts a total enterprise value of roughly $250mm based on the average valuations of comparable companies in the infectious disease and oncology arenas.”